The research and evaluation competency: The local clinical scientist—Review, current status, future directions.

2010 ◽  
pp. 125-141 ◽  
Author(s):  
Steven J. Trierweiler ◽  
George Stricker ◽  
Roger L. Peterson
Keyword(s):  
Current Status ◽  
Future Directions ◽  
Review Current

scholarly journals Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions

2021 ◽  
Vol 12 ◽  
Author(s):  
Lili Mao ◽  
Zhonghui Qi ◽  
Li Zhang ◽  
Jun Guo ◽  
Lu Si
Keyword(s):  
Current Knowledge ◽  
Checkpoint Inhibitors ◽  
Clinicopathological Characteristics ◽  
Current Status ◽  
Future Directions ◽  
Effective Interventions ◽  
Current Therapies ◽  
Melanoma Subtypes ◽  
Review Current ◽  
Pathological Subtypes

Acral and mucosal melanomas are extremely rare in Caucasians; however, they are the predominant melanoma subtypes in Asians and other non-Caucasian populations. Acral and mucosal melanomas share many clinicopathological features, including aggressive phenotypes, similar genetic landscapes, and grim prognoses. In spite of advances in melanoma management, patients with acral and mucosal melanomas show limited benefit from current therapies. The rarity of these subtypes of melanoma is a significant factor contributing to the poor understanding of these pathological subtypes and the lack of effective interventions. Furthermore, the mechanisms contributing to disparities between different types of melanoma remain largely unclear. Herein, we comprehensively review current knowledge on the clinicopathological characteristics and mutational landscapes of acral and mucosal melanomas, as well as providing an overview of current therapies for patients with these aggressive melanoma subtypes, focusing on available immunotherapeutic interventions. We also discuss pathological differences between different melanoma subtypes and summarize current knowledge on melanoma disparities between Asians and Caucasians. Finally, we discuss emerging immunotherapeutic strategies for the treatment of acral and mucosal melanomas, focusing on combination therapies with immune checkpoint inhibitors. Unraveling the unique features of acral and mucosal melanomas is key for their early diagnosis and for the development of effective therapies.

Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy

2016 ◽  
Vol 17 (8) ◽  
pp. 755-762 ◽  
Author(s):  
Xu Zhou ◽  
Renhe Liu ◽  
Shuo Qin ◽  
Ruilian Yu ◽  
Yao Fu
Keyword(s):  
Cancer Immunotherapy ◽  
Current Status ◽  
Future Directions

scholarly journals New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions

2020 ◽  
Vol 11 ◽  
Author(s):  
Nathaniel Edward Bennett Saidu ◽  
Chiara Bonini ◽  
Anne Dickinson ◽  
Magdalena Grce ◽  
Marit Inngjerdingen ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Current Status ◽  
Future Directions ◽  
Host Disease ◽  
Graft Versus Host ◽  
New Approaches

scholarly journals Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care

2021 ◽  
Author(s):  
Haoru Dong ◽  
Xinhua Shu ◽  
Qiang Xu ◽  
Chen Zhu ◽  
Andreas M. Kaufmann ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Treatment Strategies ◽  
Hpv Infection ◽  
Immune Checkpoint Blockade ◽  
Current Status ◽  
Future Directions ◽  
Sequencing Technologies ◽  
E6 And E7 ◽  
The Continuum

AbstractHuman papillomavirus (HPV) infection identified as a definitive human carcinogen is increasingly being recognized for its role in carcinogenesis of human cancers. Up to 38%–80% of head and neck squamous cell carcinoma (HNSCC) in oropharyngeal location (OPSCC) and nearly all cervical cancers contain the HPV genome which is implicated in causing cancer through its oncoproteins E6 and E7. Given by the biologically distinct HPV-related OPSCC and a more favorable prognosis compared to HPV-negative tumors, clinical trials on de-escalation treatment strategies for these patients have been studied. It is therefore raised the questions for the patient stratification if treatment de-escalation is feasible. Moreover, understanding the crosstalk of HPV-mediated malignancy and immunity with clinical insights from the proportional response rate to immune checkpoint blockade treatments in patients with HNSCC is of importance to substantially improve the treatment efficacy. This review discusses the biology of HPV-related HNSCC as well as successful clinically findings with promising candidates in the pipeline for future directions. With the advent of various sequencing technologies, further biomolecules associated with HPV-related HNSCC progression are currently being identified to be used as potential biomarkers or targets for clinical decisions throughout the continuum of cancer care.

Sign in / Sign up

Export Citation Format

Share Document